Group 1 - Hendi Pharmaceutical experienced a 5% increase in stock price, reaching 13.65 CNY per share, with a trading volume of 136 million CNY and a turnover rate of 2.41%, resulting in a total market capitalization of 5.7 billion CNY [1] - Hendi Pharmaceutical, established on December 29, 1995, is located in Jingmen City, Hubei Province, and was listed on December 22, 2021. The company specializes in the research, production, and sales of chemical raw materials and formulations [1] - The main revenue composition of Hendi Pharmaceutical includes non-steroidal anti-inflammatory drugs (68.06%), cardiovascular products (16.08%), other products (8.86%), and anti-tumor drugs (6.99%) [1] Group 2 - According to data from the top ten holdings of funds, one fund under Dongfang Fund has a significant position in Hendi Pharmaceutical. The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) held 11,600 shares in the third quarter, accounting for 0.43% of the fund's net value, ranking as the sixth largest holding [2] - The Dongfang Quantitative Multi-Strategy Mixed A Fund (006785) was established on February 22, 2019, with a latest scale of 28.7844 million CNY. The fund has achieved a year-to-date return of 10.05%, ranking 895 out of 8,836 in its category, and a one-year return of 56.94%, ranking 1,801 out of 8,091 [2] - The fund manager, Wang Huaixun, has been in position for 3 years and 243 days, with the total asset scale of the fund at 799 million CNY. During his tenure, the best fund return was 70.43%, while the worst was -0.06% [2]

Group 1 - The core viewpoint of the news is that Hendi Pharmaceutical experienced a decline in stock price and trading volume, with significant changes in financing and stockholder metrics [1][2]. Group 2 - On December 23, Hendi Pharmaceutical's stock fell by 2.35%, with a trading volume of 88.08 million yuan. The financing buy-in amount was 7.56 million yuan, while the financing repayment was 6.23 million yuan, resulting in a net financing buy of 1.33 million yuan [1]. - As of December 23, the total financing and securities lending balance for Hendi Pharmaceutical was 124 million yuan, which is 2.39% of its circulating market value, indicating a low financing balance compared to the past year [1]. - In terms of securities lending, on December 23, Hendi Pharmaceutical repaid 900 shares and sold 900 shares, with a selling amount of 11,200 yuan. The remaining securities lending volume was 22,300 shares, with a balance of 277,400 yuan, which is at a high level compared to the past year [1]. Group 3 - As of December 19, the number of shareholders for Hendi Pharmaceutical was 21,400, a decrease of 3.15%, while the average circulating shares per person increased by 3.25% to 19,531 shares [2]. - For the period from January to September 2025, Hendi Pharmaceutical reported an operating income of 319 million yuan, a year-on-year decrease of 4.52%, and a net profit attributable to shareholders of 20.93 million yuan, down 71.96% year-on-year [2]. - Since its A-share listing, Hendi Pharmaceutical has distributed a total of 378 million yuan in dividends, with 306 million yuan distributed over the past three years [2].

Core Viewpoint - The Shenzhen Stock Exchange has decided to terminate the listing of ST Puli's stock and convertible bonds due to serious financial fraud issues, marking a significant change in the company's status in the capital market [4][5]. Financial Fraud and Consequences - ST Puli was found to have inflated its profits by a total of 669 million yuan, which accounted for 73.83% of the total reported profits for 2021 and 2022 [5][6]. - The company's core management, including the chairman and general manager, were involved in orchestrating the financial fraud, leading to severe penalties including a total fine of 24.2 million yuan and market bans for key executives [6][7]. Revenue Trends - In 2020, the company reported revenue of 1.189 billion yuan, a year-on-year increase of 25.10%, and a net profit of 407 million yuan, up 35.30% [6]. - Revenue continued to grow in 2021, reaching 1.509 billion yuan (up 26.94%), but net profit only slightly increased to 417 million yuan (up 2.25%) [6]. - In 2022, revenue rose to 1.619 billion yuan (up 7.31%), but net profit fell significantly to 295 million yuan, a decrease of 29.20% [6][7]. - By 2023, revenue dropped to 1.304 billion yuan, a decline of 19.43%, with net profit plummeting to 85.92 million yuan, down 70.87% [7]. Product Performance - The company's major products, particularly cardiovascular drugs, allergy medications, antibiotics, and digestive drugs, experienced significant revenue declines in 2023 [7]. - The overall business environment for ST Puli is deteriorating, with challenges expected to intensify in 2024, despite some products showing temporary growth [7]. Market Implications - The termination of ST Puli's listing serves as a warning to the pharmaceutical industry about the importance of compliance and maintaining core competitiveness to gain market trust [7].